Sandström Maria, Laudius Maria, Lindqvist Thomas, Asklund Thomas, Johansson Mikael
Department of Radiation Sciences, Oncology Umea University, Umea, Sweden
Department of Radiation Sciences, Oncology Umea University, Umea, Sweden.
Anticancer Res. 2017 Apr;37(4):1869-1874. doi: 10.21873/anticanres.11524.
BACKGROUND/AIM: Overall survival for glioblastoma patients is short. Standard treatment is surgery followed by radiochemotherapy and adjuvant temozolomide. The aim of this study was to evaluate the outcome for all patients with progressive disease treated with bevacizumab-based treatment combinations in the northern region of Sweden.
This was a single-center retrospective analysis after bevacizumab-based second-line treatment for malignant glioma. All patients treated with bevacizumab, between 2007 and 2011 in our Center were retrospectively evaluated.
Progression-free survival after the start of bevacizumab-based treatment was 20 weeks and overall survival was 31 weeks. Treatment was well tolerated, but 9% of patients (n=6) suffered from serious adverse events. In 68% of patients, a ≥25% decrease in contrast enhancement was seen at best response.
Results from this retrospective study are comparable with earlier phase-II studies and motivate randomized trials of bevacizumab-based treatment in the second-line setting.
背景/目的：胶质母细胞瘤患者的总生存期较短。标准治疗方法是手术，随后进行放化疗及辅助替莫唑胺治疗。本研究的目的是评估瑞典北部地区所有接受以贝伐单抗为基础的联合治疗的疾病进展患者的治疗结果。
这是一项对接受以贝伐单抗为基础的二线治疗的恶性胶质瘤患者进行的单中心回顾性分析。对2007年至2011年期间在本中心接受贝伐单抗治疗的所有患者进行回顾性评估。
开始以贝伐单抗为基础的治疗后的无进展生存期为20周，总生存期为31周。治疗耐受性良好，但9%的患者（n = 6）出现严重不良事件。在68%的患者中，最佳反应时可见对比增强减少≥25%。
这项回顾性研究的结果与早期的II期研究相当，并且为二线治疗中以贝伐单抗为基础的治疗的随机试验提供了依据。
